Carlos Perdomo

4.8k total citations
87 papers, 3.3k citations indexed

About

Carlos Perdomo is a scholar working on Psychiatry and Mental health, Cognitive Neuroscience and Experimental and Cognitive Psychology. According to data from OpenAlex, Carlos Perdomo has authored 87 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Psychiatry and Mental health, 24 papers in Cognitive Neuroscience and 24 papers in Experimental and Cognitive Psychology. Recurrent topics in Carlos Perdomo's work include Sleep and related disorders (24 papers), Sleep and Wakefulness Research (22 papers) and Dementia and Cognitive Impairment Research (12 papers). Carlos Perdomo is often cited by papers focused on Sleep and related disorders (24 papers), Sleep and Wakefulness Research (22 papers) and Dementia and Cognitive Impairment Research (12 papers). Carlos Perdomo collaborates with scholars based in United States, United Kingdom and Japan. Carlos Perdomo's co-authors include Raymond Pratt, John R. Ieni, Santiago Arroyo, Gregory L. Krauss, Jacobo Mintzer, Gerhard Kluger, Tracy A. Glauser, Rajesh Sachdeo, Samantha Rogers and Jeffrey L. Cummings and has published in prestigious journals such as Circulation, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Carlos Perdomo

82 papers receiving 3.1k citations

Peers

Countries citing papers authored by Carlos Perdomo

Since Specialization

Citations

This map shows the geographic impact of Carlos Perdomo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Perdomo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Perdomo more than expected).

Fields of papers citing papers by Carlos Perdomo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carlos Perdomo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Perdomo. The network helps show where Carlos Perdomo may publish in the future.

Co-authorship network of co-authors of Carlos Perdomo

This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Perdomo. A scholar is included among the top collaborators of Carlos Perdomo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Perdomo. Carlos Perdomo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparison of the effect of lemborexant with placebo and zolpidem tartrate extended release on sleep architecture in older adults with insomnia disorder 2021 ·Journal of Clinical Sleep Medicine ·Margaret Moline, Gary Zammit, Jocelyn Y. Cheng, Carlos Perdomo, Dinesh Kumar, David Mayleben	31
2	Safety and efficacy of rufinamide in children and adults with Lennox-Gastaut syndrome: A post hoc analysis from Study 022 2021 ·Epilepsy & Behavior ·Alexis Arzimanoglou, Milka Pringsheim, Gerhard Kluger, Pierre Genton, Carlos Perdomo, Manoj Malhotra	5
3	Effectiveness and Safety of Lemborexant Over 12 Months in Adults with Insomnia Disorder: Longterm Results From the Phase 3 SUNRISE-2 Study (420) 2020 ·Neurology ·Jane Yardley, Mikko Kärppä, Yuichi Inoue, Kate Pinner, Carlos Perdomo, Gleb Filippov, Naoki Kubota, Margaret Moline	0
4	On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers 2018 ·SLEEP ·Annemiek Vermeeren, Stefan Jongen, Patricia Murphy, Margaret Moline, Gleb Filippov, Kate Pinner, Carlos Perdomo, Ishani Landry, Oneeb Majid, (unknown), C. J. Van Leeuwen, Johannes G. Ramaekers, Eric Vuurman	54
5	Dosing considerations for rufinamide in patients with Lennox–Gastaut syndrome: Phase III trial results and real-world clinical data 2017 ·Seizure ·Sanjeev V. Kothare, Gerhard Kluger, Rajesh Sachdeo, Betsy Williams, (unknown), Carlos Perdomo, Francesco Bibbiani	12
6	A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures 2010 ·Epilepsy Research ·Christian E. Elger, H. Stefan, Allison Mann, Milind M. Narurkar, Yijun Sun, Carlos Perdomo	50
7	Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: A randomized placebo‐controlled trial 2009 ·Epilepsia ·Martin J. Brodie, William E. Rosenfeld, Blanca Vázquez, Rajesh Sachdeo, Carlos Perdomo, Allison Mann, Santiago Arroyo	111
8	Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome 2008 ·Neurology ·Tracy A. Glauser, Gerhard Kluger, Rajesh Sachdeo, Gregory L. Krauss, Carlos Perdomo, Santiago Arroyo	272
9	Defining Treatment Response to Donepezil in Alzheimer’s Disease 2008 ·Drugs & Aging ·Alistair Burns, (unknown), (unknown), (unknown), Richard Y. Zhang, Elias Schwam, Carlos Perdomo	22
10	Long‐term prevention of erosive or ulcerative gastro‐oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5‐year study in the United States 2005 ·Alimentary Pharmacology & Therapeutics ·(unknown), Jeffrey R. Breiter, Carlos Perdomo, Jay Barth	39
11	Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta‐analysis of individual patient data from randomised controlled trials 2004 ·International Journal of Geriatric Psychiatry ·Anne Whitehead, Carlos Perdomo, Raymond Pratt, Jacqueline Birks, Gordon Wilcock, John Grimley Evans	120
12	Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses 2004 ·British Journal of Clinical Pharmacology ·(unknown), Sheldon Preskorn, (unknown), Dinesh Kumar, (unknown), Carlos Perdomo, Raymond Pratt	16
13	Extended in Vivo Pharmacodynamic Activity of E5564 in Normal Volunteers with Experimental Endotoxemia 2004 ·Journal of Pharmacology and Experimental Therapeutics ·Melvyn Lynn, Y. Nancy Wong, (unknown), Richard Kao, Carlos Perdomo, Robert J. Noveck, Ramón Vargas, (unknown), (unknown), F. Gilbert McMahon, Kishor M. Wasan, Daniel P. Rossignol	32
14	Steady‐state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients 2004 ·British Journal of Clinical Pharmacology ·(unknown), Ramón Vargas, Dinesh Kumar, (unknown), Carlos Perdomo, Raymond Pratt	13
15	Donepezil: A meta-analysis of individual patient data from randomized controlled trials in the treatment of patients with mild to moderate Alzheimer's disease. 2003 ·Journal of General Internal Medicine ·Carlos Perdomo, G K Wilcock, Anne Whitehead, (unknown), Jacqueline Birks, (unknown)	1
16	Blocking of Responses to Endotoxin by E5564 in Healthy Volunteers with Experimental Endotoxemia 2003 ·The Journal of Infectious Diseases ·Melvyn Lynn, Daniel P. Rossignol, (unknown), Richard Kao, Carlos Perdomo, Robert J. Noveck, Ramón Vargas, (unknown), (unknown), F. Gilbert McMahon	127
17	Donepezil: A meta-analysis of individual patient data from randomized controlled trials in the treatment of patients with mild to moderate Alzheimer's disease. 2001 ·Journal of the American Geriatrics Society ·(unknown), G K Wilcock, (unknown), Jacqueline Birks, Anne Whitehead, Carlos Perdomo	2
18	A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia 2000 ·Critical Care Medicine ·Eugene Bunnell, Melvyn Lynn, Kalim Habet, Alex Neumann, Carlos Perdomo, Lawrence Friedhoff, Sharon L. Rogers, Joseph E. Parrillo	69
19	Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease 2000 ·The American Journal of Gastroenterology ·(unknown), Moti Moskovitz, Yogeshwar Dayal, Carlos Perdomo, Robert Niecestro, Jay Barth	28
20	Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease 2000 ·European Journal of Gastroenterology & Hepatology ·C. Birbara, Jeffrey R. Breiter, Carlos Perdomo, William F. Hahne	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact